Entity Details

Primary name KCJ11_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionQ14654
EntryNameKCJ11_HUMAN
FullNameATP-sensitive inward rectifier potassium channel 11
TaxID9606
Evidenceevidence at protein level
Length390
SequenceStatuscomplete
DateCreated1997-11-01
DateModified2021-06-02

Ontological Relatives

GenesKCNJ11

GO terms

Show/Hide Table
GOName
GO:0001669 acrosomal vesicle
GO:0002931 response to ischemia
GO:0005242 inward rectifier potassium channel activity
GO:0005249 voltage-gated potassium channel activity
GO:0005524 ATP binding
GO:0005635 nuclear envelope
GO:0005739 mitochondrion
GO:0005768 endosome
GO:0005783 endoplasmic reticulum
GO:0005829 cytosol
GO:0005886 plasma membrane
GO:0005887 integral component of plasma membrane
GO:0006006 glucose metabolic process
GO:0008022 protein C-terminus binding
GO:0008282 inward rectifying potassium channel
GO:0014704 intercalated disc
GO:0015272 ATP-activated inward rectifier potassium channel activity
GO:0019829 ATPase-coupled cation transmembrane transporter activity
GO:0030315 T-tubule
GO:0030506 ankyrin binding
GO:0030673 axolemma
GO:0030955 potassium ion binding
GO:0031072 heat shock protein binding
GO:0032355 response to estradiol
GO:0033198 response to ATP
GO:0033574 response to testosterone
GO:0034765 regulation of ion transmembrane transport
GO:0042391 regulation of membrane potential
GO:0042493 response to drug
GO:0043025 neuronal cell body
GO:0043209 myelin sheath
GO:0044325 transmembrane transporter binding
GO:0046676 negative regulation of insulin secretion
GO:0050796 regulation of insulin secretion
GO:0050877 nervous system process
GO:0055085 transmembrane transport
GO:0070852 cell body fiber
GO:0071316 cellular response to nicotine
GO:0071333 cellular response to glucose stimulus
GO:0071356 cellular response to tumor necrosis factor
GO:0071805 potassium ion transmembrane transport
GO:0098662 inorganic cation transmembrane transport
GO:1903078 positive regulation of protein localization to plasma membrane
GO:1903779 regulation of cardiac conduction
GO:1990573 potassium ion import across plasma membrane
GO:2001259 positive regulation of cation channel activity

Subcellular Location

Show/Hide Table
Subcellular Location
Membrane

Domains

Show/Hide Table
DomainNameCategoryType
IPR003279 Potassium channel, inwardly rectifying, Kir6.2FamilyFamily
IPR013518 Potassium channel, inwardly rectifying, Kir, cytoplasmicFamilyHomologous superfamily
IPR014756 Immunoglobulin E-setFamilyHomologous superfamily
IPR016449 Potassium channel, inwardly rectifying, KirFamilyFamily
IPR040445 Potassium channel, inwardly rectifying, transmembrane domainDomainDomain
IPR041647 Inward rectifier potassium channel, C-terminalDomainDomain

Diseases

Show/Hide Table
Disease IDSourceNameDescription
616329 OMIMMaturity-onset diabetes of the young 13 (MODY13)A form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease. The disease is caused by variants affecting the gene represented in this entry.
601820 OMIMFamilial hyperinsulinemic hypoglycemia 2 (HHF2)Most common cause of persistent hypoglycemia in infancy. Unless early and aggressive intervention is undertaken, brain damage from recurrent episodes of hypoglycemia may occur. The disease is caused by variants affecting the gene represented in this entry.
618856 OMIMDiabetes mellitus, permanent neonatal, 2 (PNDM2)A form of permanent neonatal diabetes mellitus, a type of diabetes characterized by onset of persistent hyperglycemia within the first six months of life. Initial clinical manifestations include intrauterine growth retardation, hyperglycemia, glycosuria, osmotic polyuria, severe dehydration, and failure to thrive. Some PNDM2 patients may also have developmental delay, muscle weakness, epilepsy and dysmorphic features. PNDM2 transmission pattern is consistent with autosomal dominant inheritance. The disease is caused by variants affecting the gene represented in this entry.
610582 OMIMTransient neonatal diabetes mellitus 3 (TNDM3)Neonatal diabetes mellitus, defined as insulin-requiring hyperglycemia within the first month of life, is a rare entity. In about half of the neonates, diabetes is transient and resolves at a median age of 3 months, whereas the rest have a permanent form of diabetes. In a significant number of patients with transient neonatal diabetes mellitus, diabetes type 2 appears later in life. The onset and severity of TNDM3 is variable with childhood-onset diabetes, gestational diabetes or adult-onset diabetes described. The disease is caused by variants affecting the gene represented in this entry.

Drugs

Show/Hide Table
DrugNameSourceType
DB00222 GlimepirideDrugbanksmall molecule
DB00308 IbutilideDrugbanksmall molecule
DB00661 VerapamilDrugbanksmall molecule
DB00839 TolazamideDrugbanksmall molecule
DB00922 LevosimendanDrugbanksmall molecule
DB01016 GlyburideDrugbanksmall molecule
DB01119 DiazoxideDrugbanksmall molecule
DB01154 ThiamylalDrugbanksmall molecule
DB01392 YohimbineDrugbanksmall molecule
DB11148 ButambenDrugbanksmall molecule
DB11633 IsavuconazoleDrugbanksmall molecule